payor coverage

The deals with Stratose, USA Managed Care Organization, and Evolutions Health Systems provides covered access to the test to more than 21 million patients.

The plan will cover the gene expression test for prostate cancer aggressiveness for all men with localized disease.

Biocept's liquid biopsy diagnostic services are available to approximately 68 million people in MultiPlan's national PPO and complementary network.

Discovery's clients will be able to receive genomic sequencing services, including exome sequencing and analysis for $250 through its Vitality program.

The deal provides Tufts Health Plan members with access to the ConfirmMDx test for prostate cancer.

The agreement covers 43 million people in the US and includes Sequenom's MaterniT21 Plus and HerediT CF and Universal tests. 

The agreements with the PPOs bring the total number of Americans with covered access to Biocept's tests to about 31 million.

Starting Sept. 15, Cologuard will be available to BCBS' 500,000 members through their physicians without a co-payment or co-insurance.

The contracts with Stratose, Three Rivers Provider Network, and Fortified Provider Network provide coverage for Opko's testing services. 

The medical policy update makes the unnamed insurer the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year.